Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21640667 | 0.85 | CYP3A4 (0.52) | SLC6A9OPRD1CYP3A4CYP2C19HPGD | |
| SCHEMBL377735 | 0.83 | KMT2A (0.51) | SLC6A9MTNR1AMTNR1BOPRD1CYP3A4 | |
| SCHEMBL4793162 | 0.83 | NPSR1 (0.50) | SLC6A9HPGDCNR1CNR2HTT | |
| SCHEMBL21641014 | 0.82 | MAPT (0.56) | SLC6A9CYP3A4CYP2C19HPGDRAB9A | |
| SCHEMBL27717458 | 0.82 | CACNA1A (0.49) | SLC6A9OPRD1CNR1CNR2HTT | |
| SCHEMBL27717381 | 0.81 | SLC6A9 (0.48) | SLC6A9OPRD1CYP3A4CYP2C19CNR1 | |
| SCHEMBL13889298 | 0.81 | SLC6A9 (0.51) | SLC6A9CNR1CNR2HTTNPSR1 | |
| SCHEMBL1744817 | 0.78 | NPSR1 (0.49) | SLC6A9HPGDCNR1CNR2HTT | |
| SCHEMBL5461890 | 0.77 | ALDH1A1 (0.51) | SLC6A9OPRD1CNR1CNR2ALDH1A1 | |
| SCHEMBL2793927 | 0.76 | KMT2A (0.49) | L3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110520422-B | Novel pyridonecarboxylic acid derivative or salt thereof | 涌永制药株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| EP-3604305-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | RAB10, HDAC10, NEK10 | SLC6A9 2277/4885MTNR1A 3500/4885MTNR1B 3941/4885 |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | RARA, RAB10, RABL6 | SLC6A9 2300/4885MTNR1A 3105/4885MTNR1B 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.